Display options
Cite
Bighelli I, Castellazzi M, Cipriani A, et al. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2018;4:CD010676doi: 10.1002/14651858.CD010676.pub2.
Bighelli, I., Castellazzi, M., Cipriani, A., Girlanda, F., Guaiana, G., Koesters, M., Turrini, G., Furukawa, T. A., & Barbui, C. (2018). Antidepressants versus placebo for panic disorder in adults. The Cochrane database of systematic reviews, 4CD010676. https://doi.org/10.1002/14651858.CD010676.pub2
Bighelli, Irene, et al. "Antidepressants versus placebo for panic disorder in adults." The Cochrane database of systematic reviews vol. 4 (2018): CD010676. doi: https://doi.org/10.1002/14651858.CD010676.pub2
Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, Turrini G, Furukawa TA, Barbui C. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2018 Apr 05;4:CD010676. doi: 10.1002/14651858.CD010676.pub2. PMID: 29620793; PMCID: PMC6494573.
Copy Download .nbib Format: NLM
Share it on

Cochrane Database Syst Rev. 2018 Apr 05;4:CD010676. doi: 10.1002/14651858.CD010676.pub2.

Antidepressants versus placebo for panic disorder in adults.

The Cochrane database of systematic reviews

Irene Bighelli, Mariasole Castellazzi, Andrea Cipriani, Francesca Girlanda, Giuseppe Guaiana, Markus Koesters, Giulia Turrini, Toshi A Furukawa, Corrado Barbui

Affiliations

  1. Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, Munich, Germany.

PMID: 29620793 PMCID: PMC6494573 DOI: 10.1002/14651858.CD010676.pub2

Abstract

BACKGROUND: Panic disorder is characterised by repeated, unexpected panic attacks, which represent a discrete period of fear or anxiety that has a rapid onset, reaches a peak within 10 minutes, and in which at least four of 13 characteristic symptoms are experienced, including racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. It is common in the general population with a lifetime prevalence of 1% to 4%. The treatment of panic disorder includes psychological and pharmacological interventions. Amongst pharmacological agents, the National Institute for Health and Care Excellence (NICE) and the British Association for Psychopharmacology consider antidepressants, mainly selective serotonin reuptake inhibitors (SSRIs), as the first-line treatment for panic disorder, due to their more favourable adverse effect profile over monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Several classes of antidepressants have been studied and compared, but it is still unclear which antidepressants have a more or less favourable profile in terms of effectiveness and acceptability in the treatment of this condition.

OBJECTIVES: To assess the effects of antidepressants for panic disorder in adults, specifically:1. to determine the efficacy of antidepressants in alleviating symptoms of panic disorder, with or without agoraphobia, in comparison to placebo;2. to review the acceptability of antidepressants in panic disorder, with or without agoraphobia, in comparison with placebo; and3. to investigate the adverse effects of antidepressants in panic disorder, with or without agoraphobia, including the general prevalence of adverse effects, compared to placebo.

SEARCH METHODS: We searched the Cochrane Common Mental Disorders' (CCMD) Specialised Register, and CENTRAL, MEDLINE, EMBASE and PsycINFO up to May 2017. We handsearched reference lists of relevant papers and previous systematic reviews.

SELECTION CRITERIA: All double-blind, randomised, controlled trials (RCTs) allocating adults with panic disorder to antidepressants or placebo.

DATA COLLECTION AND ANALYSIS: Two review authors independently checked eligibility and extracted data using a standard form. We entered data into Review Manager 5 using a double-check procedure. Information extracted included study characteristics, participant characteristics, intervention details and settings. Primary outcomes included failure to respond, measured by a range of response scales, and treatment acceptability, measured by total number of dropouts for any reason. Secondary outcomes included failure to remit, panic symptom scales, frequency of panic attacks, agoraphobia, general anxiety, depression, social functioning, quality of life and patient satisfaction, measured by various scales as defined in individual studies. We used GRADE to assess the quality of the evidence for each outcome MAIN RESULTS: Forty-one unique RCTs including 9377 participants overall, of whom we included 8252 in the 49 placebo-controlled arms of interest (antidepressant as monotherapy and placebo alone) in this review. The majority of studies were of moderate to low quality due to inconsistency, imprecision and unclear risk of selection and performance bias.We found low-quality evidence that revealed a benefit for antidepressants as a group in comparison with placebo in terms of efficacy measured as failure to respond (risk ratio (RR) 0.72, 95% confidence interval (CI) 0.66 to 0.79; participants = 6500; studies = 30). The magnitude of effect corresponds to a number needed to treat for an additional beneficial outcome (NNTB) of 7 (95% CI 6 to 9): that means seven people would need to be treated with antidepressants in order for one to benefit. We observed the same finding when classes of antidepressants were compared with placebo.Moderate-quality evidence suggested a benefit for antidepressants compared to placebo when looking at number of dropouts due to any cause (RR 0.88, 95% CI 0.81 to 0.97; participants = 7850; studies = 30). The magnitude of effect corresponds to a NNTB of 27 (95% CI 17 to 105); treating 27 people will result in one person fewer dropping out. Considering antidepressant classes, TCAs showed a benefit over placebo, while for SSRIs and serotonin-norepinephrine reuptake inhibitor (SNRIs) we observed no difference.When looking at dropouts due to adverse effects, which can be considered as a measure of tolerability, we found moderate-quality evidence showing that antidepressants as a whole are less well tolerated than placebo. In particular, TCAs and SSRIs produced more dropouts due to adverse effects in comparison with placebo, while the confidence interval for SNRI, noradrenergic reuptake inhibitors (NRI) and other antidepressants were wide and included the possibility of no difference.

AUTHORS' CONCLUSIONS: The identified studies comprehensively address the objectives of the present review.Based on these results, antidepressants may be more effective than placebo in treating panic disorder. Efficacy can be quantified as a NNTB of 7, implying that seven people need to be treated with antidepressants in order for one to benefit. Antidepressants may also have benefit in comparison with placebo in terms of number of dropouts, but a less favourable profile in terms of dropout due to adverse effects. However, the tolerability profile varied between different classes of antidepressants.The choice of whether antidepressants should be prescribed in clinical practice cannot be made on the basis of this review.Limitations in results include funding of some studies by pharmaceutical companies, and only assessing short-term outcomes.Data from the present review will be included in a network meta-analysis of psychopharmacological treatment in panic disorder, which will hopefully provide further useful information on this issue.

References

  1. Acta Psychiatr Scand. 1999 Jan;99(1):51-8 - PubMed
  2. Int J Psychiatry Med. 1999;29(1):107-17 - PubMed
  3. Int Clin Psychopharmacol. 1999 May;14 Suppl 2:S13-7 - PubMed
  4. J Clin Psychiatry. 1999 Dec;60(12):831-8 - PubMed
  5. Therapie. 1999 Jul Aug;54(4):405-11 - PubMed
  6. J Psychiatry Neurosci. 2000 Jan;25(1):24-32 - PubMed
  7. Am J Psychiatry. 2000 Apr;157(4):493-505 - PubMed
  8. J Affect Disord. 2000 Apr;58(1):19-36 - PubMed
  9. JAMA. 2000 May 17;283(19):2529-36 - PubMed
  10. Pharmacopsychiatry. 2000 Sep;33(5):174-81 - PubMed
  11. Psychiatry Res. 2001 Aug 5;103(1):1-14 - PubMed
  12. Am J Psychiatry. 2001 Dec;158(12):1989-92 - PubMed
  13. Am J Psychiatry. 2001 Dec;158(12):1993-8 - PubMed
  14. Br J Psychiatry. 2001 Dec;179:514-8 - PubMed
  15. J Clin Psychiatry. 2002 Jan;63(1):31-7 - PubMed
  16. Int J Epidemiol. 2002 Feb;31(1):72-6 - PubMed
  17. Int J Epidemiol. 2002 Feb;31(1):140-9 - PubMed
  18. J Clin Psychopharmacol. 2002 Jun;22(3):275-84 - PubMed
  19. Acta Psychiatr Scand. 2002 Sep;106(3):163-7 - PubMed
  20. J Anxiety Disord. 2003;17(2):223-32 - PubMed
  21. BMJ. 2003 May 31;326(7400):1167-70 - PubMed
  22. Am J Psychiatry. 2003 Aug;160(8):1432-8 - PubMed
  23. JAMA. 2003 Aug 20;290(7):921-8 - PubMed
  24. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  25. Psychopharmacologia. 1964 Jun 8;5:397-408 - PubMed
  26. J Clin Psychiatry. 2003 Nov;64(11):1322-7 - PubMed
  27. Eur Psychiatry. 2003 Dec;18(8):401-8 - PubMed
  28. CMAJ. 2004 Feb 17;170(4):477-80 - PubMed
  29. Ann Pharmacother. 2004 Apr;38(4):579-85 - PubMed
  30. BMJ. 2004 Jun 19;328(7454):1490 - PubMed
  31. J Clin Psychopharmacol. 1992 Aug;12(4):251-61 - PubMed
  32. Br J Psychiatry. 1992 Feb;160:191-202; discussion 202-5 - PubMed
  33. Int Clin Psychopharmacol. 2005 Jan;20(1):49-52 - PubMed
  34. J Clin Psychiatry. 2005 Jan;66(1):34-40 - PubMed
  35. Neuropsychobiology. 1992;25(1):8-10 - PubMed
  36. Int Clin Psychopharmacol. 2005 Sep;20(5):265-73 - PubMed
  37. Int Clin Psychopharmacol. 2005 Nov;20(6):291-3 - PubMed
  38. Br J Psychiatry. 2005 Oct;187:352-9 - PubMed
  39. J Affect Disord. 1992 May;25(1):63-75 - PubMed
  40. J Psychopharmacol. 2005 Nov;19(6):567-96 - PubMed
  41. J Clin Epidemiol. 2006 Jan;59(1):7-10 - PubMed
  42. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(5):3-5 - PubMed
  43. Arch Gen Psychiatry. 2006 Apr;63(4):415-24 - PubMed
  44. J Clin Psychiatry. 2006 Mar;67(3):363-74 - PubMed
  45. J Clin Epidemiol. 2006 Jul;59(7):697-703 - PubMed
  46. Depress Anxiety. 2007;24(1):1-14 - PubMed
  47. Psychopharmacology (Berl). 1990;102(1):85-94 - PubMed
  48. J Clin Psychiatry. 2006 Sep;67(9):1428-34 - PubMed
  49. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004364 - PubMed
  50. Am J Psychiatry. 2007 Feb;164(2):273-5 - PubMed
  51. Psychother Psychosom. 2007;76(3):154-61 - PubMed
  52. Psychopharmacology (Berl). 2007 Oct;194(2):233-42 - PubMed
  53. Stat Med. 2008 Feb 28;27(5):746-63 - PubMed
  54. Pharmacopsychiatry. 2007 Jul;40(4):152-6 - PubMed
  55. Compr Psychiatry. 1991 Nov-Dec;32(6):559-60 - PubMed
  56. Eur Arch Psychiatry Clin Neurosci. 1991;241(3):151-8 - PubMed
  57. Eur Arch Psychiatry Clin Neurosci. 1991;240(3):163-8 - PubMed
  58. Br J Psychiatry. 2008 May;192(5):362-7 - PubMed
  59. Acta Psychiatr Scand Suppl. 1991;365:18-27 - PubMed
  60. Acta Psychiatr Scand Suppl. 1991;365:33-8 - PubMed
  61. Acta Psychiatr Scand Suppl. 1991;365:46-52 - PubMed
  62. Br J Psychiatry. 2008 Sep;193(3):229-34 - PubMed
  63. Depress Anxiety. 2009;26(10):922-9 - PubMed
  64. J Clin Psychiatry. 2009 Apr;70(4):550-61 - PubMed
  65. PLoS Med. 2009 Jul 21;6(7):e1000097 - PubMed
  66. Am J Psychiatry. 1990 Apr;147(4):507-9 - PubMed
  67. Clin Psychol Rev. 2010 Feb;30(1):37-50 - PubMed
  68. J Psychiatr Res. 1990;24 Suppl 2:27-41 - PubMed
  69. J Consult Clin Psychol. 1991 Feb;59(1):184-7 - PubMed
  70. J Clin Psychiatry. 1991 Mar;52(3):121-7 - PubMed
  71. Compr Psychiatry. 1991 Mar-Apr;32(2):120-9 - PubMed
  72. BMJ. 2010 Mar 23;340:c332 - PubMed
  73. Psychol Med. 2011 Feb;41(2):373-83 - PubMed
  74. Acta Psiquiatr Psicol Am Lat. 1990 Jan-Jun;36(1-2):59-72 - PubMed
  75. Curr Top Behav Neurosci. 2010;2:469-85 - PubMed
  76. Eur Arch Psychiatry Clin Neurosci. 1990;240(2):103-8 - PubMed
  77. Eur Arch Psychiatry Clin Neurosci. 1990;240(2):96-102 - PubMed
  78. J Clin Psychopharmacol. 1990 Apr;10(2):112-8 - PubMed
  79. J Psychopharmacol. 1993 Jan;7(4):316-24 - PubMed
  80. J Psychopharmacol. 1993 Jan;7(4):325-30 - PubMed
  81. Acta Psychiatr Scand. 1990 Nov;82(5):359-65 - PubMed
  82. Int Clin Psychopharmacol. 2013 Jan;28(1):33-45 - PubMed
  83. J Clin Psychopharmacol. 1990 Feb;10(1):3-11 - PubMed
  84. Psychopharmacol Bull. 1989;25(1):119-23 - PubMed
  85. J Affect Disord. 1989 Nov-Dec;17(3):261-70 - PubMed
  86. Arch Gen Psychiatry. 1989 Feb;46(2):127-31 - PubMed
  87. Psychopathology. 1989;22 Suppl 1:60-7 - PubMed
  88. Cochrane Database Syst Rev. 2016 Apr 13;4:CD011004 - PubMed
  89. Cochrane Database Syst Rev. 2016 Sep 12;9:CD011567 - PubMed
  90. Syst Rev. 2016 Dec 5;5(1):210 - PubMed
  91. Acta Psychiatr Scand. 1986 Jan;73(1):49-53 - PubMed
  92. Int Clin Psychopharmacol. 1987 Jan;2(1):33-45 - PubMed
  93. Psychopharmacol Bull. 1986;22(1):59-64 - PubMed
  94. Arch Gen Psychiatry. 1983 Feb;40(2):125-38 - PubMed
  95. Br J Psychiatry. 1995 Sep;167(3):374-9 - PubMed
  96. Am J Psychiatry. 1995 Oct;152(10):1438-43 - PubMed
  97. Can J Psychiatry. 1995 May;40(4):192-9 - PubMed
  98. Psychopharmacology (Berl). 1993;112(4):483-9 - PubMed
  99. Am J Psychiatry. 1994 Mar;151(3):413-20 - PubMed
  100. J Psychiatr Res. 1993;27 Suppl 1:127-42 - PubMed
  101. J Clin Psychopharmacol. 1994 Apr;14(2):107-10 - PubMed
  102. Eur Neuropsychopharmacol. 1994 Mar;4(1):47-53 - PubMed
  103. Clin Neuropharmacol. 1993 Oct;16(5):387-400 - PubMed
  104. J Clin Psychopharmacol. 1993 Oct;13(5):321-6 - PubMed
  105. J Clin Psychiatry. 1993 Dec;54(12):481-7 - PubMed
  106. Psychopharmacol Bull. 1993;29(2):183-8 - PubMed
  107. J Affect Disord. 1993 May;28(1):27-38 - PubMed
  108. Arch Gen Psychiatry. 1993 Jan;50(1):44-50 - PubMed
  109. Arch Gen Psychiatry. 1993 Jan;50(1):51-60 - PubMed
  110. Arch Gen Psychiatry. 1993 Jan;50(1):61-8 - PubMed
  111. Can J Psychiatry. 1993 Feb;38(1):19-22 - PubMed
  112. Stat Med. 1995 Sep 15;14(17):1913-25 - PubMed
  113. Braz J Med Biol Res. 1995 Sep;28(9):961-5 - PubMed
  114. Br J Psychiatry. 1995 Oct;167(4):487-94 - PubMed
  115. BMJ. 1996 Nov 9;313(7066):1200 - PubMed
  116. Psychopharmacol Bull. 1996;32(1):135-41 - PubMed
  117. Acta Psychiatr Scand. 1997 Feb;95(2):145-52 - PubMed
  118. Anxiety. 1996;2(4):192-8 - PubMed
  119. Br J Gen Pract. 1997 Mar;47(416):150-5 - PubMed
  120. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  121. Br J Psychiatry. 1997 Jun;170:549-53 - PubMed
  122. Am J Psychiatry. 1998 Jan;155(1):36-42 - PubMed
  123. Am J Psychiatry. 1998 May;155(5):603-9 - PubMed
  124. Am J Psychiatry. 1998 Sep;155(9):1189-95 - PubMed
  125. J Clin Psychiatry. 1998 Oct;59(10):528-34 - PubMed
  126. Arch Gen Psychiatry. 1998 Nov;55(11):1010-6 - PubMed
  127. Br J Psychiatry. 1998 Jul;173:54-60 - PubMed
  128. Soc Psychiatry Psychiatr Epidemiol. 1998 Dec;33(12):587-95 - PubMed
  129. J Clin Psychopharmacol. 1998 Dec;18(6 Suppl 2):12S-18S - PubMed

Substances

MeSH terms

Publication Types